Skip to content

Study · Not a test of the peptide alone · 2026

1 result

Sintilimab-related fulminant autoimmune diabetes mellitus manifesting as diabetic ketoacidosis and rare insulin resistance: A case report and literature review.

Zhang J, Zhang Y, Li H, Deng F, Ma L, Yang W, Yang H, Yu H, Chen B, Hu J

Endocrine journal10 Oct 2025

PMID41083372 (opens in a new tab)PMCIDPMC12819062 (opens in a new tab)DOI10.1507/endocrj.ej25-0295 (opens in a new tab)PepBankPUB-41083372
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneCase report or seriesSafety outcome

    In a patient with immune checkpoint inhibitor-induced diabetes, the regimen including liraglutide was discontinued because of weight loss.

    In plain wordsIn one patient, a regimen including liraglutide was stopped because of weight loss.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Metformin, dapagliflozin and liraglutide were discontinued because of weight loss half a year after discharge, and intensive insulin therapy was continued.
    1 context sentence
    Summary · context
    Here, we describe a patient with advanced myxoid liposarcoma who developed sintilimab-induced fulminant autoimmune diabetes associated with insulin resistance and metabolic disorders.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.